SGMT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SG

Mkt Cap

$568.4M

Volume

844.54K

Next Earnings

November 12th

Loading chart

SG

SGMTSagimet Biosciences Inc. Series A Common Stock

SGMT

Pay with—

Available Balance0.00

SG

Mkt Cap

$579.3M

Volume

844.54K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsightThe acne vulgaris market is expected to grow steadily through 2036, driven by increasing disease prevalence affecting 85% of adolescents and young adults, and a pipeline of emerging therapies. Key players including Ascletis Pharma, Sagimet Biosciences, AOB Pharma, and Kintor Pharmaceutical are developing novel treatments like Denifanstat (ASC40), TVB-3567, B244, and GT20029 to address unmet needs in moderate-to-severe and treatment-resistant acne. The U.S. holds the largest market share, with recent approvals including clascoterone (WINLEVI) and combination therapy CABTREO expanding treatment options.GlobeNewswire Inc. · Sep 28, 2026

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of denifanstat, a FASN inhibitor for moderate to severe acne, is on track to begin patient enrollment in Q4 2026. All clinical trial sites have been identified and a CRO has been retained, with patient screening expected to start in October 2026. The trial will enroll approximately 800 U.S. patients, including 450 adolescents, and if approved, denifanstat would be the first innovative oral acne treatment in over 40 years.GlobeNewswire Inc. · Aug 25, 2026

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® IndexesSagimet Biosciences Inc. (Nasdaq: SGMT) announced its inclusion in the Russell 3000 and Russell 2000 indexes effective June 29, 2026. The clinical-stage biopharmaceutical company plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the second half of 2026. The company has sufficient capital to fund operations through 2028, including the denifanstat Phase 3 trial data readout.GlobeNewswire Inc. · Jun 29, 2026

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Sagimet Biosciences announced management participation in the Leerink Partners Therapeutics Forum on July 15, 2026. The company also approved an inducement grant of 34,300 stock options to two newly hired employees as part of their employment compensation packages.GlobeNewswire Inc. · Jun 23, 2026

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerSagimet Biosciences appointed Dr. Andreas Grauer as Chief Medical Officer effective April 20, 2026, replacing retiring Dr. Eduardo Martins who will serve as external scientific advisor. Grauer brings over two decades of biopharmaceutical leadership experience from roles at Omeros, Federation Bio, Corcept Therapeutics, and Amgen. He received an inducement stock option grant valued at $1.34 million as part of his employment compensation.GlobeNewswire Inc. · Apr 20, 2026

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Sagimet Biosciences announced presentations of Phase 2b FASCINATE-2 trial data on denifanstat for MASH at the Fueling MASH Keystone Symposium in Vancouver. The data shows that denifanstat-treated MASH patients who were histological responders demonstrated significant reduction in glycine- and taurine-conjugated bile acids, suggesting potential use as a response biomarker. The company also approved an inducement grant of 9,600 stock options to a newly hired employee.GlobeNewswire Inc. · Apr 6, 2026

Sagimet Biosciences Announces Participation in Two Upcoming Investor ConferencesSagimet Biosciences announced that management will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26. The company is developing FASN inhibitors, with denifanstat meeting primary endpoints in Phase 2b MASH trials and Phase 3 acne trials, while a combination therapy with resmetirom is in Phase 1 testing for cirrhotic MASH patients.GlobeNewswire Inc. · Feb 5, 2026

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology ConferenceSagimet Biosciences reported positive Phase 3 clinical trial results for denifanstat in treating moderate to severe acne in China, with the drug meeting all primary and secondary endpoints and being well-tolerated.GlobeNewswire Inc. · Oct 24, 2025

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner AscletisSagimet Biosciences reported positive Phase 3 clinical trial results for denifanstat, a novel oral medication for treating moderate to severe acne, with significant improvements in lesion reduction and treatment success rates.GlobeNewswire Inc. · Sep 17, 2025

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development SummitSagimet Biosciences will present two oral presentations at the 9th Annual MASH Drug Development Summit, focusing on their FASN inhibitor denifanstat and its potential treatment for metabolic dysfunction associated steatohepatitis (MASH).GlobeNewswire Inc. · Sep 10, 2025

to start trading

SG

SGMTSagimet Biosciences Inc. Series A Common Stock

SGMT

Pay with—

Available Balance0.00

Your PositionYou don't own any SGMT yet.

Related Tickers

Earnings